Detect Cardiomyopathy and Arrhythmia

Sponsored, no-charge genetic testing
and counseling for individuals suspected
of having a familial cardiomyopathy or arrhythmia

Improve diagnosis, risk stratification, and management

Identify at-risk family members — before a life-threatening event

Post-test genetic counseling offered at no charge

Program eligibility

This program is available to individuals in the US and Canada suspected of having a familial cardiomyopathy or arrhythmia. 

Genetic testing with Invitae

The Detect Cardiomyopathy and Arrhythmia program offers the Invitae Arrhythmia and Cardiomyopathy Comprehensive Panel to test up to 150 genes associated with inherited arrhythmia and cardiomyopathy conditions.

Sponsored genetic counseling

Individuals tested through the Detect Cardiomyopathy and Arrhythmia program are eligible for post-test genetic counseling to help them understand their test results. For assistance with genetic counseling or to schedule an appointment, please click here to learn more.

Family follow-up testing

Invitae offers family variant testing for all blood relatives of patients who undergo testing at Invitae and are found to have a pathogenic or likely pathogenic variant. Our family variant testing reports on the variant(s) that was identified in the original family member, as well as any other pathogenic variant(s) found in the full gene.

If your patient tests positive through the Detect Cardiomyopathy and Arrhythmia program, all of his or her blood relatives are eligible for family variant testing. If the relatives choose to participate in the Detect Cardiomyopathy and Arrhythmia program, then the orders will be processed through the program. Download the Detect Cardiomyopathy and Arrhythmia paper order form.

Ordering made easy

Clinicians can place an order by following the steps below

Place your order

To place a paper-based order, download the paper order form. To place an order online:

  1. Sign up for an account and start a new order

  2. Under Test Selection, click on the Partnership Programs tab and enter CARDIO in the Invitae Partner Code field

  3. Use the search bar to find and select one of the testing options above

  4. Fill in the required patient information

  5. Under Billing Information, select Institutional Billing and leave all fields blank

  6. Complete the Order Authorization section and submit the order

  7. Fill out, print, and sign the eligibility criteria form, which includes a required physician consent, and include it with the specimen

Collect a specimen

  1. Order a specimen collection kit

  2. Collect the specimen and ship it back to Invitae

  3. Include the signed eligibility criteria form with the specimen

  4. For additional information, please see specimen and shipping requirements

Receive results

  1. Once Invitae receives the sample, you will receive the results in 10-21 calendar days, on average

  2. If you created an online account, you can view the status of your order by logging into your account

  3. You will receive a notification email once the test results are ready

Are you a patient?

If you're a patient and believe you are eligible for this sponsored testing program, you have options:

Contact Genome Medical
(available in US only)

Schedule a genetic counseling session, by phone or video, with an expert who can review your testing options and place the order. There is a cost associated with the Genome Medical services, which may be covered under your health benefits.

Discuss the program with your doctor

If you already have a healthcare provider who can place this order, you can download this flyer to take to your own provider.

Find a local genetics provider

Search our genetics providers network to find a provider in your area. Please sign in, or create an account, to connect with our network of professionals. There may be a cost associated with the provider’s services.

Detect Cardiomyopathy and Arrhythmia is offered in partnership with the following sponsor:


Explore relevant advocacy organizations


About Invitae

Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae provides clinical-grade, medically actionable genetic information to answer essential health questions across all stages of life.


While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing and counseling are available in the US and Canada. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any other products or services from Invitae or from third parties or commercial organizations.


  1. Towbin JA et al. 2019 HRS Expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019. doi:10.1016/j.hrthm.2019.05.007
  2. Al-Khatib SM et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72:e91-e220.
  3. Priori SG et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes.. Heart Rhythm. 2013;10:1932-63.
  4. Gersh BJ et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. J Am. Coll Cardiol. 2011;58:2703-38.
  5. Ackerman MJ et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8;1308-39.
  6. Hershberger, RE et al. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J. Card. Fail. 2018;24,281-302.